Immunogenicity of the merozoite surface protein-1 (msp-1) of human plasmodium sp.
- Author:
Cheong FW
;
Lau YL
;
Fong MY
- Publication Type:Review
- Keywords:
merozoite surface protein;
phase trials;
Plasmodium;
protective immune responses;
vaccination
- MeSH:
Malaria Vaccines
- From:Journal of University of Malaya Medical Centre
2015;18(2):1-7
- CountryMalaysia
- Language:English
-
Abstract:
Malaria is a major cause of mortality and morbidity globally. Great efforts have been made in the prevention
and the elimination of malaria, especially in controlling the malaria vector, the mosquito. Another promising
approach would be the development of malaria vaccines. Malaria vaccine studies can be focused on the
pre-erythrocytic-stage antigens and the blood-stage antigens, and on the transmission blocking agents
targeting the malaria gametocytes. The blood-stage antigens are the leading candidates in malaria vaccine
development, as the blood-stage parasites are responsible for causing symptomatic malaria. Human acquired
immunity largely targets on blood-stage antigens. This review focuses on one of the most extensively
studied blood-stage antigen, the merozoite surface protein-1 (MSP-1), specifically on its evaluation and
immunogenicity in rodents and primate models, and its safety and immunogenicity in human clinical trials.
- Full text:P020151007558964175839.pdf
